A NEW CLASS OF INDOLE ALKALOID 'ELEGANSAMINE' CONSTRUCTED FROM A MONOTERPENOID INDOLE ALKALOID AND AN IRIDOID

Dhavadee Ponglux,^a Sumphan Wongseripipatana,^a Hiromitsu Takayama,^b Koreharu Ogata,^c Norio Aimi,^b and Shin-ichiro Sakai^{b*}

Faculty of Pharmaceutical Sciences, Chulalongkorn University,^a Bangkok, 10500, THAILAND. Faculty of Pharmaceutical Sciences,^b and Chemical Analysis Center, ^c Chiba University, 1-33, Yayoi-cho, Chiba 260, JAPAN.

<u>Summary</u> Elegansamine (1) isolated from *Gelsemium elegans* (Thailand) was proved to be a new type of alkaloid composed by the carbon-carbon linkage of a monoterpenoid indole alkaloid and a monoterpene unit having the iridoid skeleton.

As part of our continuing research on the chemistry of *Gelsemium* alkaloids, (1)-3) the investigation of the alkaloid constituents of the branches of *Gelsemium* elegans resulted in the isolation of a new alkaloid, named elegansamine. We disclose herein the structure of this minor alkaloid having hitherto unencountered type of constitution.

From the methanol extracts of the branches collected in Thailand, elegansamine (1) was obtained as colorless prisms, mp.172-173.°C (MeOH), together with nine known bases, i.e. gelsemine, gelsevirine, koumine, gelsenicine (2), 14-hydroxygelsenicine, humantenine, 19-(Z)-akuammidine, and koumidine. Elegansamine (1) showed the UV spectrum characteristic to N(a)-methoxy oxindole nucleus. High resolution mass spectrum showed the M^+ 508.2572, corresponding to the formula C29H36N2O6 (Calcd. 508.2571), and gave the base peak m/z 326, corresponding to the molecular weight of gelsenicine (2)(C19H22N2O3), indicating that elegansamine (1) was constructed from gelsenicine (2) or its isomer and a monoterpene unit containing three oxygen atom.

In the ¹H-NMR spectrum (CDCl₃), in addition to some readily assignable signals due to gelsenicine moiety such as four aromatic protons (δ 7.50 C₉-H, δ 7.26 C₁₁-H, δ 7.07 C₁₀-H, δ 6.89 C₁₂-H), N-OMe (δ 3.95 3H,s), C₃-H (δ 3.70 1H, dd, J=4.9 and 2.2Hz), C₁₅-H (δ 2.91 1H, t-like, J=9Hz), and C₁₆-H (δ 2.54 1H, m.), characteristic signals of a doublet on C₁₈ protons (δ 1.47 3H, J=7.3Hz) and a multiplet due to C₁₉ proton (δ 2.66) were observed in place of the ethyl group in gelsenicine (2), suggesting that monoterpene unit might be connected at C₁₉ position. From the ¹³C-NMR spectrum of (1) (see Table), the composing indole alkaloid part and the monoterpene unit were respectively demonstrated to be gelsenicine and an iridoid skeleton, which possessed a lactone function, a C-Me group, and a secondary hydroxy group.

At this stage X-ray structural analysis was carried out. The crystal of elegansamine (1) had the following crystal data: monoclinic, P21, a=10.701(3), b=7.940(2), c=17.039(4)Å, Z=2, Cell volume=1415Å³, Dc=1.26 gcm⁻³. A total of 3115 unique independent intensities were measured within the range of $3\leq 20\leq 120^\circ$, 150° on a four-circle diffractometer (Rigaku

AFC-5) using CuK α radiation (λ =1.54Å). The structure was solved by the direct method using MULTAN 80 and refined anisotropically (isotropically for H) by the least-squares method to an R value of 0.0496, using the 2834 reflections for which F(0)>3 σ (Fo). The ORTEP drawing is shown in Fig. The CD spectrum of (1) closely resembles that of gelsenicine (2)⁵) and therefore gelsenicine part and the iridoid residue in (1) have the same absolute configuration as the conventional indole alkaloids and iridoid monoterpenes, respectively.

0^{-17} 16 R=H (2)	(2) Table ${}^{13}\text{C-NMR}^{4)}$		
	No.	(2)	(1)
	2	172.1(s)	171.5(s)
$\frac{1}{5}$ $\frac{1}{20}$ $\frac{1}{19}$ $R = 0$	3	74.9(d)*	75.0(d)
	5	72.5(d)*	72.5(d)
	6	37.7(t)	37.4(t)
H_{N_5}	7	55.8(s)	56.1(s)
	8	132.3(s)	131.9(s)
	9	124.6(d)	124.7(d)
	10	123.3(d)	123.4(d)
7' 8' Me	11	128.0(d)	128.1(d)
	12	106.5(d)	106.6(d)
	13	138.0(s)	138.0(s)
1 1 1	14	25.6(t)	27.7(t)
	15	39.8(d)**	40.1(d)
17	16	42.5(d)**	42.5(d)
20	17	62.1(t)	61.9(t)
	18	10.0(q)	19.3(q)*
	19	25.6(1)	37.7(d)**
	20	184.1(s)	186.2(s)
	-OMe	63.3(q)	63.2(q)
	1'		70.4(t)
A A A	3'		177.9(s)
	4'		48.7(d)
	5'		37.7(d)**
	6'		71.2(d)
	7'		43.7(t)
(Меон) 📈 😿	8'		35.1(d)**
	9'		45.1(d)
•	10'		18.7(q)*
Fig. ORTEP Drawing of (1)	11'		33.1(t)

References and Notes

- 1) S. Sakai, E. Yamanaka, M. Kitajima, M. Yokota, N. Aimi, S. Wongseripipatana, and D. Ponglux, <u>Tetrahedron Lett.</u>, 27, 4585 (1986).
- 2) S. Sakai, S. Wongseripipatana, D. Ponglux, M. Yokota, K. Ogata, H. Takayama, and N. Aimi, <u>Chem.</u> <u>Pharm. Bull</u>. 35, 4668 (1987).
- D. Ponglux, S. Wongseripipatana, S. Subhadhirasakul, H. Takayama, M. Yokota, K. Ogata, C. Phisalaphong, N. Aimi, and S. Sakai, <u>Tetrahedron</u>, 44, 0000 (1988).
- 4) Chemical shift in ppm downfield from TMS. Solvent; CDCl3. Signals bearing the same superscript may be interchangeable within vertical column.
- 5) CD spectral data: (1)(c=0.95x10⁻², MeOH, 23°C) [θ]₃₁₂0, [θ]₂₆₀-18200, [θ]_{245.5}0, [θ]₂₃₄+18200, [θ]₂₂₂0, [θ]₂₀₉-59000. (2)(c=1.0x10⁻², MeOH, 23°C) [θ]₃₁₄0, [θ]₂₆₂-24200, [θ]_{248.5}0, [θ]₂₃₄+39300, [θ]₂₂₁0, [θ]₂₁₁-73300.

(Received in Japan 16 August 1988)